CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
放射治疗、Wim's Tumor 1 (WT1) 树突状细胞疫苗治疗与α-半乳糖神经酰胺脉冲树突状细胞疫苗治疗联合用于终末期小肠癌
英文原题：Combination of Radiation Therapy, Wim's Tumor 1 (WT1) Dendritic Cell Vaccine Therapy, and α-Galactosylceramide-Pulsed Dendritic Cell Vaccine Therapy for End-Stage Small Bowel Cancer.
查看英文原题
Combination of Radiation Therapy, Wim's Tumor 1 (WT1) Dendritic Cell Vaccine Therapy, and α-Galactosylceramide-Pulsed Dendritic Cell Vaccine Therapy for End-Stage Small Bowel Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对于不再对手术、放疗或化疗产生反应的终末期癌症患者，尚无确立的治疗方法，姑息治疗是全球标准。我们对一名40岁男性终末期小肠癌患者进行了调强放射治疗以缓解疼痛，该患者在化疗无效后被判定预期寿命为两个月。随后给予七剂识别WT1和α-半乳糖神经酰胺抗原的树突状细胞疫苗，导致癌症显著缩小并明显改善患者的一般状况。放疗与树突状细胞疫苗疗法的联合治疗可能抑制癌症进展并延长生存期，即使在化疗难治性终末期癌症患者中也是如此。特别是，使用WT1和α-半乳糖神经酰胺脉冲树突状细胞的双重树突状细胞疫苗疗法可能提供优于各自单一疗法的抗肿瘤免疫效果。
展开英文摘要原文
There is no established treatment for terminal cancer patients who no longer respond to surgery, radiotherapy, or chemotherapy, and palliative care is the standard worldwide.
We performed intensity-modulated radiation therapy for pain relief in a 40-year-old male patient with end-stage small intestinal cancer who had been diagnosed with a life expectancy of two months after chemotherapy had been ineffective. Subsequent administration of seven doses of dendritic cell vaccine recognizing Wim's tumor 1 (WT1) and α-galactosylceramide antigens resulted in significant shrinkage of the cancer and marked improvement of the patient's general condition.
The combination therapy of radiotherapy and dendritic cell vaccine therapy may suppress cancer progression and prolong survival, even in patients with chemotherapy-refractory terminal cancer. In particular, double dendritic cell vaccine therapy with WT1 and α-galactosylceramide-pulsed dendritic cell may provide an anti-tumor immune effect that is superior to that of the respective monotherapy.
论文信息
- 作者
- Nagai H、Chen H、Karube R、Koitabashi Y、Numata O、Yamahara K
- 第一作者单位
- Department of Human Development - Environment and Resources, Graduate School of Human and Environmental Studies, Tokai University, Kanagawa, JPN.Japan
- 通讯作者单位
- Laboratory of Molecular and Cellular Therapy, Institute for Advanced Medical Sciences, Hyogo Medical University, Hyogo, JPN.Japan
- 文献类型
- 病例报告
- 期刊
- Cureus2024 Jul
- 原文标识
- PubMed 39035592 · DOI 10.7759/cureus.64972
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →